menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Ventyx Biosciences Reports Q4 and Full Year 2024 Financials

    GLOBENEWSWIRE

    Ventyx Presents Ph 2 TYK2 Inhibitor VTX958 Data In Crohn’s At ECCO

    GLOBENEWSWIRE

    Ventyx to Participate in Oppenheimer Annual Healthcare Conference

    GLOBENEWSWIRE

    Ventyx Biosciences Shares 2025 Strategy, Updates on NLRP3 Portfolio

    GLOBENEWSWIRE

    Ventyx Bio to Participate in 3 Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Reports Q3 2024 Financial Results & Progress

    GLOBENEWSWIRE

    Ventyx Biosciences Presents 52-Week Results From Phase 2 Trial

    GLOBENEWSWIRE

    Sanofi makes $27M equity investment in Ventyx

    FIERCE BIOTECH

    Ventyx Starts Phase 2a Trial Of VTX3232 In Early Parkinson`s Disease

    GLOBENEWSWIRE

    Ventyx Biosciences Announces Departure of Chief Financial Officer

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Reports Q2 2024 Results And Highlights Progress

    GLOBENEWSWIRE

    Ventyx Reports Phase 2 Results Of VTX958 In Crohn`s Disease

    GLOBENEWSWIRE

    Ventyx`s last hope for inflammatory med ends in phase 2 Crohn`s failure

    FIERCE BIOTECH

    Ventyx Bio: CNS NLRP3 Inhibitor Shows Metabolic/Inflammatory Benefits

    GLOBENEWSWIRE

    Ventyx Appoints Matthew Moore As Chief Operating Officer

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Q1 2024 Financials And Corporate Progress

    GLOBENEWSWIRE

    Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

    GLOBENEWSWIRE

    Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio

    GLOBENEWSWIRE

    Ventyx Biosciences Announces $100 Million Private Placement of Common Stock

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024

    GLOBENEWSWIRE

    Ventyx Biosciences earnings beat by $0.08

    PRESS RELEASE

    Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

    GLOBENEWSWIRE

    Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Conference

    GLOBENEWSWIRE

    Ventyx to Participate in the 35th Annual Piper Sandler Healthcare Conference

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

    GLOBENEWSWIRE

    Ventyx Biosciences Reports Third Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Ventyx stock drops 70% as TYK2 inhibitor psoriasis plans halted

    FIERCE BIOTECH

    Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958

    GLOBENEWSWIRE

    Ventyx misses with investors amid comparisons to BMS, Pfizer

    FIERCE BIOTECH

    Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002

    GLOBENEWSWIRE

    Ventyx Insider Sold Shares Worth $449,699, According to a Recent SEC Filing

    PRESS RELEASE

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Reports Second Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Ventyx Bio to Report Second Quarter 2023 Financial Results on August 10, 2023

    GLOBENEWSWIRE

    Ventyx to Participate in the Canaccord Genuity 43rd Annual Growth Conference

    GLOBENEWSWIRE

    Why did Ventyx Biosciences stock drop today? Large shareholder sale

    SEEKING ALPHA

    Why Shares of Ventyx Biosciences Rose Monday

    FOOL

    Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232

    GLOBENEWSWIRE

    Ventyx Bio Announces Completion of Enrollment of the Phase 2 Trial of VTX002

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Reports First Quarter 2023 Financial Results

    GLOBENEWSWIRE

    Ventyx Biosciences to Report 1Q FYR 2023 on May 11, 2023

    GLOBENEWSWIRE

    Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q4 2022 Earnings Call Transcript

    FINANCE YAHOO

    Ventyx to Participate in the H.C. Wainwright Autoimmune Conference

    GLOBENEWSWIRE

    Ventyx Biosciences 4Q & 2022 FYR and Highlights Recent Corporate Progress

    GLOBENEWSWIRE

    Ventyx to Report Fourth Quarter and Full Year 2022 Financial Results

    GLOBENEWSWIRE

    Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Announces Highlights Strategic Priorities at Investor R&D Day

    GLOBENEWSWIRE

    Ventyx Appoints Allison J. Hulme and Onaiza Cadoret-Manier to Board of Directors

    GLOBENEWSWIRE

    Ventyx Biosciences to Host R&D Event on January 26, 2023

    GLOBENEWSWIRE

    Ventyx Announces Dosing of First Patient in the Ph2 SERENITY Trial of VTX958

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx Biosciences Reports 3Q FYR and Highlights Recent Corporate Progress

    GLOBENEWSWIRE

    Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

    GLOBENEWSWIRE

    Ventyx seeks to rack up $176M+ in its move as the market become bullish on TYK2

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.